U.S. investment in new treatments is often driven by market potential rather than medical necessity, deepening health disparities and costing lives. Researchers say these recommendations could help.

Global rare disease policy shifts are reshaping orphan drug development, with major implications for equitable access in the UK, EU and US.

As drug costs rise and public trust falls, A.I. may transform the economics of clinical trials—and reshape the future of pharma. Unsplash+ Sixty percent of the total U.S. population takes at least one ...

AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...

SHANGHAI, China, October 29, 2025 (EZ Newswire) -- WuXi AppTec, opens new tab, a global contract research, development, and manufacturing organization (CRDMO), recently hosted its 2025 Investor Day, ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ...